JP5745774B2 - 多重定量的核酸増幅及び融解アッセイ - Google Patents
多重定量的核酸増幅及び融解アッセイ Download PDFInfo
- Publication number
- JP5745774B2 JP5745774B2 JP2010052206A JP2010052206A JP5745774B2 JP 5745774 B2 JP5745774 B2 JP 5745774B2 JP 2010052206 A JP2010052206 A JP 2010052206A JP 2010052206 A JP2010052206 A JP 2010052206A JP 5745774 B2 JP5745774 B2 JP 5745774B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- target nucleic
- melting
- labeled
- amplification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims description 129
- 108020004707 nucleic acids Proteins 0.000 title claims description 121
- 102000039446 nucleic acids Human genes 0.000 title claims description 121
- 238000002844 melting Methods 0.000 title claims description 117
- 230000008018 melting Effects 0.000 title claims description 117
- 238000003199 nucleic acid amplification method Methods 0.000 title claims description 59
- 230000003321 amplification Effects 0.000 title claims description 56
- 238000003556 assay Methods 0.000 title description 38
- 239000000523 sample Substances 0.000 claims description 94
- 238000000034 method Methods 0.000 claims description 41
- 238000003753 real-time PCR Methods 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 239000007850 fluorescent dye Substances 0.000 claims description 16
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 15
- 239000002751 oligonucleotide probe Substances 0.000 claims description 15
- 101710163270 Nuclease Proteins 0.000 claims description 14
- 230000008859 change Effects 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 10
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 29
- 238000001514 detection method Methods 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 19
- 238000009396 hybridization Methods 0.000 description 17
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 238000011002 quantification Methods 0.000 description 10
- 101000595252 Homo sapiens Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Proteins 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 108091093088 Amplicon Proteins 0.000 description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 101000684495 Homo sapiens Sentrin-specific protease 1 Proteins 0.000 description 7
- 102100023653 Sentrin-specific protease 1 Human genes 0.000 description 7
- 102100036033 Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Human genes 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 238000007846 asymmetric PCR Methods 0.000 description 6
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 238000000137 annealing Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000007837 multiplex assay Methods 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 4
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 229930010555 Inosine Natural products 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 241000589596 Thermus Species 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 2
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 241000589497 Thermus sp. Species 0.000 description 2
- 241000589499 Thermus thermophilus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- -1 etc.) Chemical compound 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
- 101150042997 21 gene Proteins 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- 108010037497 3'-nucleotidase Proteins 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LQQGJDJXUSAEMZ-UAKXSSHOSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LQQGJDJXUSAEMZ-UAKXSSHOSA-N 0.000 description 1
- XXSIICQLPUAUDF-TURQNECASA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C#CC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XXSIICQLPUAUDF-TURQNECASA-N 0.000 description 1
- HRDXGYQCVPZEJE-UAKXSSHOSA-N 4-amino-5-bromo-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HRDXGYQCVPZEJE-UAKXSSHOSA-N 0.000 description 1
- LOFVQBRIYOQFDZ-UAKXSSHOSA-N 4-amino-5-chloro-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Cl)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LOFVQBRIYOQFDZ-UAKXSSHOSA-N 0.000 description 1
- LMNPKIOZMGYQIU-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrimidine-2,4-dione Chemical compound FC(F)(F)C1=CNC(=O)NC1=O LMNPKIOZMGYQIU-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- OZQDLJNDRVBCST-SHUUEZRQSA-N 5-amino-2-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazin-3-one Chemical compound O=C1N=C(N)C=NN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 OZQDLJNDRVBCST-SHUUEZRQSA-N 0.000 description 1
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- FBLNVVJQCGUTHY-FDDDBJFASA-N BrC=CC=1C(=NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C1)=O)N Chemical compound BrC=CC=1C(=NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C1)=O)N FBLNVVJQCGUTHY-FDDDBJFASA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 241000192091 Deinococcus radiodurans Species 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 238000001327 Förster resonance energy transfer Methods 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010059000 Protein Phosphatase 1 Proteins 0.000 description 1
- 102000005569 Protein Phosphatase 1 Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000042303 SPRING family Human genes 0.000 description 1
- 108091078185 SPRING family Proteins 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 241000204666 Thermotoga maritima Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 241000589501 Thermus caldophilus Species 0.000 description 1
- 241000589498 Thermus filiformis Species 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 108010068032 caltractin Proteins 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- LBSANEJBGMCTBH-UHFFFAOYSA-N manganate Chemical compound [O-][Mn]([O-])(=O)=O LBSANEJBGMCTBH-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
定義
「非対称PCR」は、2つの増幅プライマーの量が等しくないPCRである。より多量に存在するプライマーは「過剰プライマー」と呼ばれ、より少量に存在するプライマーは「制限プライマー」と呼ばれる。過剰プライマーの伸長から得られる鎖が過剰に蓄積され、「過剰鎖」」と呼ばれる。他の鎖は、制限プライマーの伸長から得られ、より少量に蓄積され、「制限鎖」と呼ばれる。
融解に基づく増殖曲線を用いた、同一チューブにおける様々な量の標的SENP1及びPPP1CAの定量的増幅
この実施例では、方法は、組織試料における様々な量のSENP1及びPPP1CA RNAの検出及び定量に適用された。
Q−BHQ−2クエンチャー色素
E−tert−ブチル−ベンジルdA
p−3’−リン酸基
Claims (9)
- 単一の試料容器中で、1以上の標的核酸を同時多重リアルタイムPCRで増幅、検出及び定量するための方法であって、
(a)1以上の標的核酸を含むことが疑われる試料と、少なくとも1セットのオリゴヌクレオチドプローブとを接触させ、該セットに含まれる各オリゴヌクレオチドプローブは、同一の1以上のレポーター部分を用いて標識され、ここで、該標識オリゴヌクレオチドプローブの各々は、
i.少なくとも1つの核酸の少なくとも部分配列(subsequence)に十分に相補的であり;
ii.同一セットに含まれる他の標識オリゴヌクレオチドプローブの融点とは異なっている融点を有する対応する標的核酸に結合することができ;
(b)温度変化間隔を含む増幅反応のサイクルにおいて、試料中の標的核酸を増幅させ、ここで、該標識オリゴヌクレオチドプローブは対応する標的核酸とのハイブリッドから解離し;
(c)少なくとも一部分の該温度変化間隔にわたって、該レポーター部分からの発光を検出し;
(d)少なくとも前記一部分の温度変化間隔にわたって、工程(c)で検出された該発光の一次導関数をプロットし;
(e)工程(d)でプロットされた該導関数の最大値を決定し;
(f)工程(b)から(e)を複数回繰り返し;及び
(g)工程(b)から(e)のサイクル数又は繰り返しの数に対して、工程(e)で検出された該導関数の最大値をプロットし、工程(e)で決定された値の所定の閾値に到達する繰り返し数を決定し、このようにして該標的核酸の相対量を定量する
ことを含む方法。 - 既知濃度の対照核酸を標的核酸(複数)と同時に工程(a)〜(f)に供し、各標的核酸についての工程(g)で決定された値が、対照核酸についての工程(g)で決定された値と比較され、それにより各々の該標的核酸の絶対量を決定する、請求項1に記載の方法。
- 工程(a)における該オリゴヌクレオチドプローブの各々は、単一のレポーター部分を用いて標識される、請求項1及び2のいずれか1項に記載の方法。
- 前記レポーター部分が蛍光性である、請求項3に記載の方法。
- 工程(a)における該オリゴヌクレオチドプローブの各々は、レポーター部分とクエンチャー部分を用いて標識される、請求項1又は2に記載の方法。
- 前記レポーター部分と前記クエンチャー部分は蛍光色素分子である、請求項5に記載の方法。
- 前記レポーター部分は蛍光色素分子であり、前記クエンチャー部分はダーククエンチャーである、請求項5に記載の方法。
- 前記レポーター部分と前記クエンチャー部分はヌクレアーゼ切断部位によって分けられる、請求項5に記載の方法。
- 工程(b)の前に、試料中の標的核酸を増幅するために少なくとも1回の増幅サイクルをさらに含む、請求項1〜8のいずれか1項に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/400,966 US8039215B2 (en) | 2009-03-10 | 2009-03-10 | Multiplex quantitative nucleic acid amplification and melting assay |
US12/400,966 | 2009-03-10 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010207220A JP2010207220A (ja) | 2010-09-24 |
JP2010207220A5 JP2010207220A5 (ja) | 2013-04-25 |
JP5745774B2 true JP5745774B2 (ja) | 2015-07-08 |
Family
ID=42224157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010052206A Active JP5745774B2 (ja) | 2009-03-10 | 2010-03-09 | 多重定量的核酸増幅及び融解アッセイ |
Country Status (6)
Country | Link |
---|---|
US (1) | US8039215B2 (ja) |
EP (1) | EP2228454B1 (ja) |
JP (1) | JP5745774B2 (ja) |
CN (1) | CN101831496B (ja) |
CA (1) | CA2696652C (ja) |
ES (1) | ES2589102T3 (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1585974B1 (en) | 2003-01-24 | 2013-02-27 | University of Utah | Methods of predicting mortality risk by determining telomere length |
US8951939B2 (en) * | 2011-07-12 | 2015-02-10 | Bio-Rad Laboratories, Inc. | Digital assays with multiplexed detection of two or more targets in the same optical channel |
US9921154B2 (en) | 2011-03-18 | 2018-03-20 | Bio-Rad Laboratories, Inc. | Multiplexed digital assays |
US9689028B2 (en) * | 2008-12-22 | 2017-06-27 | University Of Utah Foundation | Monochrome multiplex quantitative PCR |
US8039215B2 (en) | 2009-03-10 | 2011-10-18 | Roche Molecular Systems, Inc. | Multiplex quantitative nucleic acid amplification and melting assay |
CN102576389B (zh) * | 2009-10-21 | 2016-08-03 | 皇家飞利浦电子股份有限公司 | 用于扩增反应的分析工具 |
CN103534360A (zh) | 2011-03-18 | 2014-01-22 | 伯乐生命医学产品有限公司 | 借助对信号的组合使用进行的多重数字分析 |
JP6059453B2 (ja) * | 2011-05-31 | 2017-01-11 | アークレイ株式会社 | 同一又は近傍の検出波長を有する蛍光色素で修飾された複数のオリゴヌクレオチドを用いて、1種類の波長で複数の遺伝子多型を検出する方法 |
JP5570657B2 (ja) * | 2011-10-31 | 2014-08-13 | アークレイ株式会社 | 遺伝子存在量の測定方法 |
WO2013074962A1 (en) * | 2011-11-16 | 2013-05-23 | Canon U.S. Life Sciences, Inc. | Mutation detection in higly homologous genomic regions |
WO2013113748A1 (en) * | 2012-02-02 | 2013-08-08 | Primer Design Ltd | Method for detecting and genotyping target nucleic acid |
CN104271767B (zh) | 2012-02-03 | 2017-08-25 | 加州理工学院 | 多路生化测定中信号的编码和解码 |
US9791372B2 (en) | 2012-08-03 | 2017-10-17 | California Institute Of Technology | Multiplexing and quantification in PCR with reduced hardware and requirements |
US9970052B2 (en) | 2012-08-23 | 2018-05-15 | Bio-Rad Laboratories, Inc. | Digital assays with a generic reporter |
CN102952794B (zh) * | 2012-09-05 | 2015-02-25 | 张家港蓝苏生物工程有限公司 | 靶向基因dna分子探针的制备方法 |
CA2880583C (en) | 2012-09-10 | 2021-02-16 | Randy P. Rasmussen | Multiple amplification cycle detection |
KR101943623B1 (ko) * | 2013-03-13 | 2019-01-30 | 주식회사 씨젠 | 멜팅 피크 분석을 이용한 타겟 핵산서열의 정량 |
ES2762860T3 (es) | 2013-05-22 | 2020-05-26 | Telomere Diagnostics Inc | Medidas de abundancia de telómeros cortos |
WO2015147370A1 (en) * | 2014-03-28 | 2015-10-01 | Seegene, Inc. | Detection of target nucleic acid sequences using different detection temperatures |
EP3034617A1 (en) | 2014-12-16 | 2016-06-22 | Marcos Isamat Riviere | Method for the simultaneous identification of multiple same-genome fragments or multiple fragments from different genomes using a PCR-technique |
JP2018501799A (ja) | 2014-12-30 | 2018-01-25 | テロメア ダイアグノスティクス インコーポレイテッド | マルチプレックス定量的pcr |
SG11201708920PA (en) * | 2015-06-04 | 2017-11-29 | Mizuho Medy Co Ltd | Kit for together detecting multiple target nucleic acids differing from each other and detection method using the same |
WO2017173035A1 (en) | 2016-04-01 | 2017-10-05 | Chromacode Inc. | Competitive probes for engineering signal generation |
EP3472354A4 (en) * | 2016-06-17 | 2020-01-01 | California Institute of Technology | NUCLEIC ACID ACTIONS AND RELATED PROCEDURES AND COMPOSITIONS |
US11313000B2 (en) | 2016-08-04 | 2022-04-26 | Duke University | Compositions and methods for measuring bacterial growth |
KR102468174B1 (ko) * | 2016-09-15 | 2022-11-17 | 에프. 호프만-라 로슈 아게 | 멀티플렉스 pcr 수행 방법 |
CN106868140B (zh) * | 2017-03-02 | 2022-10-18 | 北京酷搏科技有限公司 | 多重荧光定量pcr的方法 |
US20190093155A1 (en) * | 2017-05-25 | 2019-03-28 | Roche Molecular Systems, Inc. | Multiplex Nucleic Acid Amplification Assay |
EP3697927B1 (en) * | 2017-10-19 | 2022-12-14 | Bio-Rad Laboratories, Inc. | Digital amplification assays with unconventional and/or inverse changes in photoluminescence |
BR112020014412A2 (pt) * | 2018-01-22 | 2020-12-29 | Luminex Corporation | Métodos e composições para análise de fusão discreta |
CN112004941B (zh) | 2018-04-20 | 2023-10-27 | Seegene株式会社 | 用于检测样品中的多个靶核酸序列的方法及装置 |
WO2023023533A1 (en) * | 2021-08-19 | 2023-02-23 | Luminex Corporation | Digital amplification assay analysis method |
WO2023125552A1 (zh) * | 2021-12-27 | 2023-07-06 | 迈克生物股份有限公司 | 对靶标核酸进行检测的方法 |
WO2024006927A1 (en) * | 2022-06-29 | 2024-01-04 | Life Technologies Corporation | Compositions, kits, and methods for detecting nucleic acids using intra-channel multiplexing |
CN117701689A (zh) * | 2022-09-14 | 2024-03-15 | 迈克生物股份有限公司 | 多重pcr反应体系 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE3529478A1 (de) | 1985-08-16 | 1987-02-19 | Boehringer Mannheim Gmbh | 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung |
US5466591A (en) | 1986-08-22 | 1995-11-14 | Hoffmann-La Roche Inc. | 5' to 3' exonuclease mutations of thermostable DNA polymerases |
US5374553A (en) | 1986-08-22 | 1994-12-20 | Hoffmann-La Roche Inc. | DNA encoding a thermostable nucleic acid polymerase enzyme from thermotoga maritima |
US5455170A (en) | 1986-08-22 | 1995-10-03 | Hoffmann-La Roche Inc. | Mutated thermostable nucleic acid polymerase enzyme from Thermus species Z05 |
US5405774A (en) | 1986-08-22 | 1995-04-11 | Hoffmann-La Roche Inc. | DNA encoding a mutated thermostable nucleic acid polymerase enzyme from thermus species sps17 |
US5795762A (en) | 1986-08-22 | 1998-08-18 | Roche Molecular Systems, Inc. | 5' to 3' exonuclease mutations of thermostable DNA polymerases |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
AU658378B2 (en) | 1990-09-28 | 1995-04-13 | F. Hoffmann-La Roche Ag | Purified thermostable nucleic acid polymerase enzyme from thermosipho africanus |
JPH04234422A (ja) | 1990-10-31 | 1992-08-24 | Internatl Business Mach Corp <Ibm> | 二重硬化エポキシバックシール処方物 |
DE4234086A1 (de) | 1992-02-05 | 1993-08-12 | Diagen Inst Molekularbio | Verfahren zur bestimmung von in vitro amplifizierten nukleinsaeuresequenzen |
US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
GB9513271D0 (en) | 1995-06-29 | 1995-09-06 | Johnson James G | Stress free fish harvester |
US5773258A (en) | 1995-08-25 | 1998-06-30 | Roche Molecular Systems, Inc. | Nucleic acid amplification using a reversibly inactivated thermostable enzyme |
CA2257109C (en) * | 1996-06-04 | 2009-10-06 | University Of Utah Research Foundation | Monitoring hybridization during pcr |
US6427156B1 (en) | 1997-01-21 | 2002-07-30 | Xilinx, Inc. | Configurable logic block with AND gate for efficient multiplication in FPGAS |
US6228628B1 (en) | 1997-07-09 | 2001-05-08 | Roche Molecular Systems | Mutant chimeric DNA polymerase |
US6140054A (en) | 1998-09-30 | 2000-10-31 | University Of Utah Research Foundation | Multiplex genotyping using fluorescent hybridization probes |
US6472156B1 (en) * | 1999-08-30 | 2002-10-29 | The University Of Utah | Homogeneous multiplex hybridization analysis by color and Tm |
US20040053230A1 (en) * | 2001-03-07 | 2004-03-18 | Schaffer Michael Edward | Real time quantitative pcr with intercalating dye for single and multiplex target dna |
US7019129B1 (en) * | 2000-05-09 | 2006-03-28 | Biosearch Technologies, Inc. | Dark quenchers for donor-acceptor energy transfer |
CA2400601A1 (en) | 2001-08-31 | 2003-02-28 | University Of Utah Research Foundation | Real-time gene quantification with internal standards |
WO2004074447A2 (en) | 2003-02-18 | 2004-09-02 | Applera Corporation | Compositions and methods for multiplex analysis of polynucleotides |
US20050053950A1 (en) * | 2003-09-08 | 2005-03-10 | Enrique Zudaire Ubani | Protocol and software for multiplex real-time PCR quantification based on the different melting temperatures of amplicons |
WO2006040187A2 (en) * | 2004-10-11 | 2006-04-20 | Epigenomics Ag | A method for the carry-over protection in dna amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids |
ES2668467T3 (es) * | 2004-10-18 | 2018-05-18 | Brandeis University | Métodos de amplificación LATE y secuenciación de un ácido nucleico |
US20070072211A1 (en) | 2005-06-30 | 2007-03-29 | Roche Molecular Systems, Inc. | Asymmetric PCR coupled with post-PCR characterization for the identification of nucleic acids |
JP4815980B2 (ja) * | 2005-10-05 | 2011-11-16 | 株式会社島津製作所 | 融解曲線測定による遺伝子増幅産物の解析方法 |
US20100285468A1 (en) | 2007-09-24 | 2010-11-11 | Allelogic Biosciences Corporation | Detection and/or quantification of nucleic acids |
EP2116614A1 (en) | 2008-05-06 | 2009-11-11 | Qiagen GmbH | Simultaneous detection of multiple nucleic acid sequences in a reaction |
US8039215B2 (en) | 2009-03-10 | 2011-10-18 | Roche Molecular Systems, Inc. | Multiplex quantitative nucleic acid amplification and melting assay |
-
2009
- 2009-03-10 US US12/400,966 patent/US8039215B2/en active Active
-
2010
- 2010-03-08 EP EP10002350.6A patent/EP2228454B1/en active Active
- 2010-03-08 ES ES10002350.6T patent/ES2589102T3/es active Active
- 2010-03-09 JP JP2010052206A patent/JP5745774B2/ja active Active
- 2010-03-09 CA CA2696652A patent/CA2696652C/en active Active
- 2010-03-10 CN CN201010163977.7A patent/CN101831496B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
EP2228454B1 (en) | 2016-06-22 |
CA2696652C (en) | 2015-09-08 |
JP2010207220A (ja) | 2010-09-24 |
ES2589102T3 (es) | 2016-11-10 |
US8039215B2 (en) | 2011-10-18 |
CA2696652A1 (en) | 2010-09-10 |
CN101831496B (zh) | 2017-04-12 |
CN101831496A (zh) | 2010-09-15 |
US20100233686A1 (en) | 2010-09-16 |
EP2228454A1 (en) | 2010-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5745774B2 (ja) | 多重定量的核酸増幅及び融解アッセイ | |
KR102246600B1 (ko) | 핵산 검정에서 개선된 용융 판별 및 멀티플렉싱을 위한 프로브 | |
CA2747068C (en) | Nucleic acid amplification with allele-specific suppression of sequence variants | |
EP2337865B1 (en) | Allele-specific amplification using a primer with a modified nucleotide | |
CA2733903C (en) | Proofreading primer extension | |
KR102371222B1 (ko) | 표적핵산 증폭방법 및 표적핵산 증폭용 조성물 | |
US20100143901A1 (en) | Nuclease-Free Real-Time Detection of Nucleic Acids | |
US20160369330A1 (en) | Compositions for improved allele-specific pcr | |
US20120070831A1 (en) | Amplification of Distant Nucleic Acid Targets Using Engineered Primers | |
KR102370550B1 (ko) | Egfr 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트 | |
CA2781133C (en) | Preferential amplification of mrna over dna using chemically modified primers | |
EP2071041A1 (en) | Nucleic acid detection probe | |
JP5774990B2 (ja) | 蛍光標識及び可溶性消光体を使用する標的変異体の検出 | |
WO2009067664A1 (en) | Photoinduced electron transfer (pet) primer for nucleic acid amplification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130307 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130307 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141029 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150407 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150507 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5745774 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |